An Interventional Study to Evaluate Treating to a Target of Transmural Healing in Patients With Moderately to Severely Active Crohn's Disease
Latest Information Update: 26 Aug 2026
At a glance
- Drugs Vedolizumab (Primary) ; Adalimumab; Budesonide; Infliximab; Prednisone; Risankizumab; Risankizumab; Upadacitinib; Ustekinumab; Ustekinumab
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms VECTORS
Most Recent Events
- 14 Aug 2024 Status changed from not yet recruiting to recruiting.
- 16 Feb 2024 New trial record